CA2789945A1 - Universal virus-like particle (vlp) influenza vaccines - Google Patents

Universal virus-like particle (vlp) influenza vaccines Download PDF

Info

Publication number
CA2789945A1
CA2789945A1 CA2789945A CA2789945A CA2789945A1 CA 2789945 A1 CA2789945 A1 CA 2789945A1 CA 2789945 A CA2789945 A CA 2789945A CA 2789945 A CA2789945 A CA 2789945A CA 2789945 A1 CA2789945 A1 CA 2789945A1
Authority
CA
Canada
Prior art keywords
influenza
vlp
cell
proteins
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2789945A
Other languages
English (en)
French (fr)
Inventor
Jose Galarza
George R. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technovax Inc
Original Assignee
Technovax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technovax Inc filed Critical Technovax Inc
Publication of CA2789945A1 publication Critical patent/CA2789945A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2789945A 2010-02-18 2011-02-18 Universal virus-like particle (vlp) influenza vaccines Pending CA2789945A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30576810P 2010-02-18 2010-02-18
US30575910P 2010-02-18 2010-02-18
US61/305,759 2010-02-18
US61/305,768 2010-02-18
PCT/US2011/000300 WO2011102900A1 (en) 2010-02-18 2011-02-18 Universal virus-like particle (vlp) influenza vaccines

Publications (1)

Publication Number Publication Date
CA2789945A1 true CA2789945A1 (en) 2011-08-25

Family

ID=44483229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789945A Pending CA2789945A1 (en) 2010-02-18 2011-02-18 Universal virus-like particle (vlp) influenza vaccines

Country Status (6)

Country Link
US (4) US9352031B2 (enExample)
EP (1) EP2536428B1 (enExample)
JP (2) JP2013520167A (enExample)
CN (1) CN102858368B (enExample)
CA (1) CA2789945A1 (enExample)
WO (1) WO2011102900A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
CN103154021A (zh) * 2010-08-16 2013-06-12 威斯特解剖及生物研究所 通用甲型流感疫苗
WO2013044203A2 (en) * 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
RU2682752C2 (ru) * 2011-09-30 2019-03-21 Медикаго Инк. Повышение выхода вирусоподобных частиц в растениях
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
IN2014DN07152A (enExample) 2012-03-22 2015-04-24 Fraunhofer Usa Inc
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102199018B1 (ko) 2013-03-28 2021-01-07 메디카고 인코포레이티드 식물에서 인플루엔자 바이러스-유사 입자 생산
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
SG11201602522VA (en) * 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
EP3089755A1 (en) 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
CN106559986A (zh) * 2014-06-20 2017-04-05 美国政府(由卫生和人类服务部的部长所代表) 多价流感病毒样颗粒(vlp)及其作为疫苗的用途
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
CN110167585B (zh) 2016-09-02 2024-03-08 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
MX2023012554A (es) 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.
CN110272473B (zh) * 2019-07-10 2021-03-02 军事科学院军事医学研究院军事兽医研究所 甲型流感通用型病毒样颗粒及其制备方法和应用
EP3896077A1 (en) * 2020-04-16 2021-10-20 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Influenza virus-like particles (vlps)
US20230321219A1 (en) * 2020-08-17 2023-10-12 Technovax, Inc. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES
AU2021342576A1 (en) * 2020-09-21 2023-04-06 University Of Georgia Research Foundation, Inc. PIV5-based covid-19 vaccine
CN112342149A (zh) * 2020-11-12 2021-02-09 新疆畜牧科学院兽医研究所（新疆畜牧科学院动物临床医学研究中心） 一种禽流感病毒样颗粒组装表达系统及其应用
US20250325649A1 (en) * 2021-12-31 2025-10-23 Mynvax Private Limited Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof
CN120053630B (zh) * 2025-04-28 2025-07-18 中国医学科学院医学生物学研究所 一种广谱流感疫苗的抗原表位肽组合及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
JP2009502789A (ja) * 2005-07-19 2009-01-29 ダウ グローバル テクノロジーズ インコーポレイティド 組み換えインフルエンザワクチン
PT1937301E (pt) * 2005-10-18 2015-09-14 Novavax Inc Partículas idênticas a vírus (vlps) da gripe funcionais
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
WO2008061243A2 (en) * 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
US8883479B2 (en) * 2008-11-25 2014-11-11 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
CA2787099A1 (en) * 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
WO2011102900A1 (en) * 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
KR102072582B1 (ko) * 2012-12-31 2020-02-03 엘지전자 주식회사 듀얼 디스플레이 방법 및 장치

Also Published As

Publication number Publication date
JP2013520167A (ja) 2013-06-06
JP6524555B2 (ja) 2019-06-05
US11529410B2 (en) 2022-12-20
US20160303223A1 (en) 2016-10-20
EP2536428A1 (en) 2012-12-26
US20110212128A1 (en) 2011-09-01
CN102858368A (zh) 2013-01-02
US20190091323A1 (en) 2019-03-28
JP2016198107A (ja) 2016-12-01
US20200297836A1 (en) 2020-09-24
US9352031B2 (en) 2016-05-31
EP2536428A4 (en) 2014-04-09
US10080796B2 (en) 2018-09-25
EP2536428B1 (en) 2018-12-05
US10695418B2 (en) 2020-06-30
CN102858368B (zh) 2017-04-12
WO2011102900A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
US11529410B2 (en) Universal virus-like particle (VLP) influenza vaccines
US9387241B2 (en) Influenza virus-like particle (VLP) compositions
US9101578B2 (en) Polyvalent influenza virus-like particle (VLP) compositions
US20110097358A1 (en) RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10548968B2 (en) Functional influenza virus-like particles (VLPS)
JP6643239B2 (ja) 免疫原性の中東呼吸器症候群コロナウイルス（ＭＥＲＳ−ＣｏＶ）組成物および方法
US11324816B2 (en) Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
US7507411B2 (en) Attenuated influenza NS1 variants
KR101847908B1 (ko) 광견병 당단백질 바이러스-유사 입자(VLPs)
US8795682B2 (en) Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
US9884105B2 (en) Production of viral vaccine
CA2525953A1 (en) High titer recombinant influenza viruses for vaccines and gene therapy
CN114929269A (zh) 用于疫苗开发的改进的流感病毒复制
CA2452119A1 (en) Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US20130189303A1 (en) Recombinant swine influenza virus and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160218